A New AI Model can Accurately Predict Human Response to Novel Drug Compounds

The journey between identifying a potential therapeutic compound and Food and Drug Administration approval of a new drug can take well over a decade and cost upwards of a billion dollars. A research team at the CUNY Graduate Center has created an artificial intelligence model that could significantly improve the accuracy and reduce the time and cost of the drug development process. Described in a newly published paper in Nature Machine Intelligence, the new model, called CODE-AE, can screen novel drug compounds to accurately predict efficacy in humans. In tests, it was also able to theoretically identify personalized drugs for over 9,000 patients that could better treat their conditions. Researchers expect the technique to significantly accelerate drug discovery and precision medicine.

Accurate and robust prediction of patient-specific responses to a new chemical compound is critical to discover safe and effective therapeutics and select an existing drug for a specific patient. However, it is unethical and infeasible to do early efficacy testing of a drug in humans directly. Cell or tissue models are often used as a surrogate of the human body to evaluate the therapeutic effect of a drug molecule. Unfortunately, the drug effect in a disease model often does not correlate with the drug efficacy and toxicity in human patients. This knowledge gap is a major factor in the high costs and low productivity rates of drug discovery.

"Our new machine learning model can address the translational challenge from disease models to humans," said Lei Xie, a professor of computer science, biology and biochemistry at the CUNY Graduate Center and Hunter College and the paper's senior author. "CODE-AE uses biology-inspired design and takes advantage of several recent advances in machine learning. For example, one of its components uses similar techniques in Deepfake image generation."

The new model can provide a workaround to the problem of having sufficient patient data to train a generalized machine learning model, said You Wu, a CUNY Graduate Center Ph.D. student and co-author of the paper. "Although many methods have been developed to utilize cell-line screens for predicting clinical responses, their performances are unreliable due to data incongruity and discrepancies,” Wu said. “CODE-AE can extract intrinsic biological signals masked by noise and confounding factors and effectively alleviated the data-discrepancy problem."

As a result, CODE-AE significantly improves accuracy and robustness over state-of-the-art methods in predicting patient-specific drug responses purely from cell-line compound screens.

The research team's next challenge in advancing the technology's use in drug discovery is developing a way for CODE-AE to reliably predict the effect of a new drug's concentration and metabolization in human bodies. The researchers also noted that the AI model could potentially be tweaked to accurately predict human side effects to drugs.

This work was supported by the National Institute of General Medical Sciences and the National Institute on Aging.

He D, Liu Q, Wu Y et al.
A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening.
Nat Mach Intell, 2022. doi: 10.1038/s42256-022-00541-0

Most Popular Now

Artificial Intelligence: Unexpected Resu…

Artificial intelligence (AI) is on the rise. Until now, AI applications generally have "black box" character: How AI arrives at its results remains hidden. Prof. Dr. Jürgen Bajorath, a cheminformatics...

Printed Robots with Bones, Ligaments, an…

3D printing is advancing rapidly, and the range of materials that can be used has expanded considerably. While the technology was previously limited to fast-curing plastics, it has now been...

AI identifies Non-Smokers at High Risk f…

Using a routine chest X-ray image, an artificial intelligence (AI) tool can identify non-smokers who are at high risk for lung cancer, according to a study being presented next week...

Orchestrating the New World of AI in Hea…

Orion Health's UK and Ireland Customer Conference 2023 focused on the future potential and immediate, practical application of AI to healthcare - and gave delegates a first look at the...

Study Reveals Bias in AI Tools when Diag…

Machine learning algorithms designed to diagnose a common infection that affects women showed a diagnostic bias among ethnic groups, University of Florida researchers found. While artificial intelligence (AI) tools offer...

Researchers Take New AI Approach to Anal…

Researchers at Karolinska Institutet and SciLifeLab in Sweden have combined artificial intelligence (AI) techniques used in satellite imaging and community ecology to interpret large amounts of data from tumour tissue...

Medical AI Tool from UF, NVIDIA gets Hum…

A new artificial intelligence (AI) computer program created by researchers at the University of Florida and NVIDIA can generate doctors' notes so well that two physicians couldn't tell the difference...

Commission Opens Calls to Invest €42 Mil…

Today, the European Commission opened a new set of calls for proposals under the 2023-2024 Work Programmes of the Digital Europe Programme with a focus on advanced digital skills. The calls...

Bayer Championing Advancements in Radiol…

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence...

MEDICA and COMPAMED: Medical Technology …

13 - 16 November 2023, Düsseldorf, Germany. After four days of business, MEDICA and COMPAMED in Düsseldorf delivered impressive confirmation that they are excellent platforms for the worldwide medical technology business...

AI Predicts Developmental Paths in Prema…

Researchers at UMC Utrecht have developed an AI model to predict long-term outcome in extremely premature babies early in life. The model can identify which infants might face intellectual disability...

AI Paves Way for New Medicines

A team of researchers from LMU, ETH Zurich, and Roche Pharma Research and Early Development (pRED) Basel has used artificial intelligence (AI) to develop an innovative method that predicts the...